Carisma Therapeutics Stock Quote CARM - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.106

Bid

1.10

Ask

1.11

Volume

43,866

1.07 Day's Range 1.11

0.99 52 Week Range 8.5899

Market Cap

45.946M

Previous Close

1.10

Open

1.07

Last Trade

104

1.106

Last Trade Time

11:55:20

Financial Volume

$ 47,918

VWAP

1.0924

Average Volume (3m)

852,826

Shares Outstanding

41,542,744

Dividend Yield

PE Ratio

-0.53

Earnings Per Share (EPS)

-2.09

Revenue

14.92M

Net Profit

-86.88M

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.carismatx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was $1.10. Over the last year, Carisma Therapeutics shares have traded in a share price range of $ 0.99 to $ 8.5899.

Carisma Therapeutics currently has 41,542,744 shares outstanding. The market capitalization of Carisma Therapeutics is $45.70 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.53.

Form 8-K - Current report

Carmila: Resources Devoted to the Liquidity Contract as of 30 June 2024

Regulatory News: At 30 June 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CA) with Kepler Cheuvreux were the following: - 80,485 CARMILA shares; - Euro...

CARMILA: Information Concerning the Total Number of Voting Rights and Share

provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des marchés financiers (General regulation of...

Carmila: Closing of the Acquisition of Galimmo SCA

Carmila announces the closing of the acquisition of 93% of the share capital of Galimmo SCA Galimmo’s portfolio of 52 assets, mainly located in the North-East of France, was valued at 675...

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, July 1, 2024 Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and...

Carmila : Participation dans Galimmo SCA potentiellement portée à 99,9%

Regulatory News: Le 28 juin 2024, Carmila (Paris:CARM) a consenti à une entité gérée par Primonial REIM France une promesse unilatérale d’achat portant sur l’intégralité de la participation...

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna PR Newswire PHILADELPHIA, June 27, 2024...

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors PR Newswire PHILADELPHIA, June 25, 2024 Fast Track designation highlights...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.174	-13.59375	1.28	1.38	1.03	328844	1.18441153	CS
4	-0.044	-3.82608695652	1.15	1.9	1.03	2196776	1.44829567	CS
12	-0.564	-33.7724550898	1.67	1.9	0.99	852826	1.4292755	CS
26	-1.344	-54.8571428571	2.45	2.77	0.99	476197	1.56787481	CS
52	-7.234	-86.7386091127	8.34	8.5899	0.99	343297	2.32013684	CS
156	-4.684	-80.8981001727	5.79	9.7662	0.99	323279	3.24170434	CS
260	-4.684	-80.8981001727	5.79	9.7662	0.99	323279	3.24170434	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF	20.10 (839.25%)	128.72k
RGCRegencell Bioscience Holdings Ltd	$ 10.64 (215.73%)	85.36k
SLRXSalarius Pharmaceuticals Inc	$ 4.2999 (179.21%)	42.77M
ADILAdial Pharmaceuticals Inc	$ 1.7394 (64.09%)	145.29M
SPWRSunPower Corporation	$ 1.0887 (52.10%)	100.18M
RNAZTransCode Therapeutics Inc	$ 0.2998 (-62.17%)	6.02M
JAGXJaguar Health Inc	$ 1.6292 (-61.85%)	9.71M
MIRAMIRA Pharmaceuticals Inc	$ 2.3338 (-53.42%)	19.88M
FLYEFly E Group Inc	$ 3.44 (-46.08%)	6.31M
CMAXCareMax Inc	$ 3.2602 (-37.18%)	7.1M
ADILAdial Pharmaceuticals Inc	$ 1.7394 (64.09%)	145.29M
SPWRSunPower Corporation	$ 1.0887 (52.10%)	100.18M
SLNASelina Hospitality PLC	$ 0.02475 (-33.11%)	94.21M
ATPCAgape ATP Corporation	$ 0.1905 (33.22%)	90.37M
NVDANVIDIA Corporation	$ 123.615 (0.06%)	84.76M